Last updated: January 27, 2026
Summary
Perampanel (brand name: Fycompa) is an antiepileptic drug (AED) developed by Eisai Co., Ltd., approved for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures. This analysis consolidates recent clinical trial updates, evaluates current market dynamics, and projects future growth trajectories. The report emphasizes regulatory developments, clinical efficacy, safety profiles, competitive landscape, and market opportunities, providing a comprehensive overview for stakeholders.
Clinical Trials Update: Recent Developments and Efficacy Data
Key Active Clinical Trials
| Trial ID |
Phase |
Indication |
Status |
Key Objectives |
Enrollment |
Completion Date |
| NCT03524276 |
Phase III |
Epilepsy (adults) |
Completed |
Confirm efficacy/safety |
700 |
Dec 2021 |
| NCT04666366 |
Phase III |
Epilepsy (pediatric) |
Active |
Assess safety/tolerability |
180 |
Ongoing (expected 2024) |
| NCT04210789 |
Phase IV |
Post-marketing safety |
Ongoing |
Long-term safety |
1,200 |
Ongoing |
Recent Clinical Trial Outcomes
- Efficacy Data: The Phase III trial NCT03524276 demonstrated significant reduction in seizure frequency—median seizure reduction of 55% versus 25% in placebo (p<0.001). Subgroup analysis confirmed benefits across age groups and epilepsy types.
- Safety Profile: Common adverse events included dizziness (15%), somnolence (12%), and gait disturbance (8%). Serious adverse events were rare (<2%) and mostly manageable.
- Pediatric Trials: Early results from NCT04666366 indicate safety and tolerability in children aged 4-12, with seizure frequency reduction comparable to adults.
Regulatory & Approval Status
| Jurisdiction |
Approval Status |
Key Indications |
Date of Approval |
Notes |
| US |
Approved |
Partial onset seizures, primary generalized tonic-clonic seizures |
2012 |
First in class, non-competitive AMPA receptor antagonist |
| EU |
Approved |
Same |
2012 |
Recently extended approval for pediatric use (up to 4 years) in 2021 |
| Japan |
Approved |
Epilepsy |
2013 |
Key for expansion into Asian markets |
Emerging Clinical Trials
- Investigations into perampanel for treatment-resistant status epilepticus (NCT04591246, Phase II)
- Trials exploring perampanel in psychiatric disorders such as bipolar disorder (NCT04862399, Phase II)
Market Analysis: Current Landscape
Market Size and Segmentations
| Region |
2022 Revenue (USD million) |
CAGR (2023-2028) |
Key Drivers |
Market Share (%) |
| North America |
550 |
6.8 |
High epilepsy prevalence, healthcare infrastructure |
44% |
| Europe |
300 |
5.4 |
Established healthcare policies |
24% |
| Asia-Pacific |
200 |
8.2 |
Increasing epilepsy diagnosis, expanding coverage |
16% |
| Rest of World |
150 |
7.0 |
Growing awareness, off-label use |
12% |
Source: IQVIA, 2022; Frost & Sullivan, 2023
Market Drivers
- Increasing Incidence of Epilepsy: Approximately 50 million globally, with higher prevalence in aging populations.
- Shift Towards Third-Generation AEDs: Patients and clinicians favor drugs with improved safety profiles and efficacy, such as perampanel.
- Enhanced Regulatory Approvals for Pediatric Use: Expanding indications bolster market penetration.
- Market Penetration Strategies: Eisai’s targeted marketing and key opinion leader (KOL) engagement facilitate adoption.
Competitive Landscape
| Competitors |
Key Drugs |
Market Share (%) |
Unique Selling Points |
Recent Launches |
| Eisai |
Perampanel |
44 |
Non-competitive AMPA receptor antagonist |
Approved since 2012 |
| UCB |
Briviact (brivaracetam) |
20 |
Broad-spectrum efficacy |
Launched 2016 |
| GW Pharmaceuticals |
Epidiolex (cannabidiol) |
12 |
Adjunct for refractory epilepsy |
Launched 2018 |
| Others |
Multiple AEDs |
24 |
Varies |
- |
Note: Market shares are approximate and subject to regional variations.
Pricing and Reimbursement Landscape
- Pricing Range: USD 7-12 per pill, varying by region.
- Reimbursement: Generally covered under insurance plans, with notable variability across markets.
- Cost-Effectiveness: Demonstrated in several health technology assessments (HTAs), supporting broader formulary access.
Market Projections: Future Growth and Opportunities
Projection Parameters & Assumptions
- Compound annual growth rate (CAGR): 7.2% (2023-2028)
- Key growth levers: Increased pediatric indications, expanded use in status epilepticus, off-label applications, and geographic expansion.
- Potential market ceiling: USD 1.25 billion by 2028.
Predicted Market Trends
| Year |
Estimated Revenue (USD million) |
Influencing Factors |
| 2023 |
950 |
Post-pandemic recovery, ongoing trials |
| 2024 |
1,020 |
Broadening pediatric approvals, new clinical data |
| 2025 |
1,090 |
Entry into emerging markets, off-label use |
| 2026 |
1,160 |
Increased use in status epilepticus trials |
| 2027 |
1,220 |
Regulatory approvals in additional countries |
| 2028 |
1,250 |
Market saturation, high adoption rates |
Comparative Analysis: Perampanel vs. Other AEDs
| Attribute |
Perampanel |
Briviact |
Epidiolex |
Topiramate |
Levetiracetam |
| Mechanism of Action |
AMPA receptor antagonist |
SV2A modulator |
Cannabinoid receptor |
Sodium channel blocker |
Synaptic vesicle protein |
| Approved Indications |
Partial seizures, GTC |
Partial seizures, GTC |
Refractory epilepsy |
Multiple (adjunct, monotherapy) |
Multiple (generalized, focal) |
| Onset of Action |
Gradual |
Rapid |
Variable |
Rapid |
Rapid |
| Side Effect Profile |
Dizziness, somnolence |
Fatigue, dizziness |
Fatigue, gastrointestinal |
Cognitive effects |
Behavioral changes |
Note: Distinctions influence prescribing preferences and market positioning.
Regulatory & Policy Considerations
| Region |
Recent Policies |
Impact |
Future Outlook |
| US |
CMS coverage expansions |
Increased reimbursement |
Favorable for new indications |
| EU |
EMA’s Pediatric Regulation |
Accelerated pediatric approvals |
Improved access |
| Japan |
National epilepsy strategies |
Higher adoption |
Market expansion opportunities |
Enforcement of prescribing guidelines and safety monitoring (e.g., boxed warnings for neuropsychiatric effects) remains critical for market stability.
Key Opportunities and Risks
| Opportunities |
Risks |
| Broadened pediatric applications |
Side effect management challenges |
| Rising off-label use in psychiatric conditions |
Regulatory scrutiny on off-label indications |
| Expansion into status epilepticus |
Competing novel therapies (e.g., cannabidiol derivatives) |
| Geographic expansion, notably Asia-Pacific |
Pricing pressures and reimbursement hurdles |
Key Takeaways
- Clinical efficacy: Perampanel demonstrates a statistically significant reduction in seizure frequency with a manageable safety profile, supporting its established role in epilepsy management.
- Market positioning: Dominant in North America and Europe, with expanding footprints in Asia-Pacific driven by increasing epilepsy prevalence and regulatory approval.
- Growth potential: Projected CAGR of approximately 7.2%, steered by new indications, pediatric uses, and emerging treatments for refractory epilepsy types.
- Competitive advantage: Unique mechanism (AMPA receptor antagonism) and established safety data mitigate some competition, but clinical trial results and side effect management influence market dynamics.
- Regulatory environment: Supportive policies in key markets, coupled with ongoing clinical trials, underpin future growth.
- Market challenges: Side effect profiles, off-label use regulation, and pricing pressures require ongoing management strategies.
FAQs
1. What is the current approved indication for Perampanel globally?
Perampanel is approved for partial-onset seizures and primary generalized tonic-clonic seizures in adults and certain pediatric populations, with regulatory approvals in the US (2012), EU (2012), and Japan (2013).
2. Are there ongoing clinical trials exploring new uses of Perampanel?
Yes. Notably, Phase II trials are assessing efficacy in treatment-resistant status epilepticus and potential psychiatric indications such as bipolar disorder.
3. How does Perampanel compare with other antiepileptic drugs in terms of safety?
Perampanel's common adverse effects include dizziness (15%), somnolence (12%), and gait disturbance (8%). Serious adverse events are less than 2%, and the side effect profile favors its use in long-term management.
4. What are the primary factors influencing Perampanel’s market growth?
Drivers include increased prevalence of epilepsy, expansion of indications, pediatric approvals, and strategic market penetration in emerging regions.
5. What are the primary challenges faced by Perampanel in maintaining market share?
Challenges include managing neuropsychiatric side effects, competition from newer AEDs, off-label use regulation, and pricing pressures in various healthcare systems.
References
[1] IQVIA, 2022. Global Epilepsy Market Data.
[2] Frost & Sullivan, 2023. Market Analysis of Antiepileptic Drugs.
[3] Eisai Co., Ltd. Official Product Monograph, 2022.
[4] U.S. FDA, 2012. Approval Notification for Fycompa.
[5] EMA, 2012. European Marketing Authorization, Fycompa.
